0.4193 -0.021 (-4.7%) | 02-18 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.67 | 1-year : | 0.83 |
Resists | First : | 0.58 | Second : | 0.71 |
Pivot price | 0.46 ![]() |
|||
Supports | First : | 0.36 | Second : | 0.3 |
MAs | MA(5) : | 0.43 ![]() |
MA(20) : | 0.45 ![]() |
MA(100) : | 0.57 ![]() |
MA(250) : | 0.68 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 23.3 ![]() |
D(3) : | 25.5 ![]() |
RSI | RSI(14): 42.8 ![]() |
|||
52-week | High : | 1.26 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NAOV ] has closed above bottom band by 28.8%. Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.45 - 0.45 | 0.45 - 0.46 |
Low: | 0.4 - 0.4 | 0.4 - 0.4 |
Close: | 0.42 - 0.42 | 0.42 - 0.42 |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
Fri, 14 Feb 2025
NanoVibronix acquires enteral tech firm ENvue Medical - MSN
Fri, 14 Feb 2025
Strategic Medical Tech Acquisition: NanoVibronix Takes Over Enteral Feeding Pioneer ENvue - StockTitan
Fri, 24 Jan 2025
NanoVibronix stock touches 52-week low at $0.44 amid market challenges - MSN
Tue, 07 Jan 2025
NanoVibronix Unveils Next-Gen PainShield and UroShield with Enhanced Therapy Features - StockTitan
Mon, 06 Jan 2025
NanoVibronix's UroShield Completes Key Clinical Trial Phase at University of Michigan - StockTitan
Wed, 11 Dec 2024
NanoVibronix Secures $12M Distribution Deal for PainShield in Major Non-Opioid Pain Management Partnership - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 6 (M) |
Shares Float | 4 (M) |
Held by Insiders | 0.1 (%) |
Held by Institutions | 9 (%) |
Shares Short | 1,660 (K) |
Shares Short P.Month | 250 (K) |
EPS | -1.24 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.67 |
Profit Margin | -93.9 % |
Operating Margin | -258 % |
Return on Assets (ttm) | -26.6 % |
Return on Equity (ttm) | -94.1 % |
Qtrly Rev. Growth | -17.9 % |
Gross Profit (p.s.) | 0.31 |
Sales Per Share | 0.53 |
EBITDA (p.s.) | -0.42 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -2 (M) |
Levered Free Cash Flow | -1 (M) |
PE Ratio | -0.35 |
PEG Ratio | 0 |
Price to Book value | 0.62 |
Price to Sales | 0.78 |
Price to Cash Flow | -1.05 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |